• Explore /
  • Poster
  • / VISION: An international, prospective, open-label, multicenter, randomized phase III study of 177Lu-PSMA-617 in the treatment of patients with progressive PSMA-positive metastatic castration-resistant prostate cancer (mCRPC).

VISION: An international, prospective, open-label, multicenter, randomized phase III study of 177Lu-PSMA-617 in the treatment of patients with progressive PSMA-positive metastatic castration-resistant prostate cancer (mCRPC).

Abstract Poster

Authors

A. Sartor

A. Oliver Sartor

Tulane Cancer Center, New Orleans, LA

A. Oliver Sartor , Michael J. Morris , Richard Messman , Bernd J. Krause

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2020 Genitourinary Cancers Symposium

Session Type

Trials in Progress Poster Session

Session Title

Trials in Progress Poster Session A: Prostate Cancer

Track

Prostate Cancer - Advanced,Prostate Cancer - Localized

Sub Track

Therapeutics

Clinical Trial Registration Number

NCT03511664

Citation

J Clin Oncol 38, 2020 (suppl 6; abstr TPS259)

Abstract #

TPS259

Poster Bd #

P3

Abstract Disclosures

Similar Posters

First Author: Gliceida Galarza Fortuna

First Author: A. Oliver Sartor

First Author: Soumaya Labidi

First Author: Ridvan Arda Demirci